Tandem Diabetes Company Leadership
TNDM Stock | USD 35.15 2.38 6.34% |
Tandem Diabetes employs about 2.4 K people. The company is managed by 15 executives with a total tenure of roughly 30 years, averaging almost 2.0 years of service per executive, having 160.0 employees per reported executive. Analysis of Tandem Diabetes' management performance can provide insight into the firm performance.
Brian Hansen President Chief Commercial Officer, Executive Vice President |
Leigh Vosseller President Senior Vice President - Finance |
Tandem Diabetes' Insider Buying Vs Selling
50
Selling | Buying |
Latest Trades
2024-11-20 | Kim D Blickenstaff | Disposed 10000 @ 30 | View | ||
2024-11-15 | Mark David Novara | Acquired 532 @ 23.24 | View | ||
2024-08-05 | Josh Gottheimer | Acquired @ 40.79 | |||
2024-05-30 | Dick Allen | Disposed 5000 @ 51.68 | View |
Monitoring Tandem Diabetes' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Acquired vs Disposed
Filed vs Not Filed
Insider sentiment refers to the collective sentiment or feeling of Tandem Diabetes' insiders - typically its officers, directors, and beneficial owners holding more than a certain percentage of the company's stock - about the future prospects of Tandem Diabetes Care. This sentiment is often gauged based on the trading activities of these insiders. If insiders are purchasing more shares of their own company, it may be interpreted as a bullish sentiment, indicating that they believe Tandem Diabetes' stock will rise in value. Conversely, if insiders are selling shares, it might be seen as bearish, suggesting they expect the stock price to drop.
Tandem |
Tandem Diabetes' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Tandem Diabetes' future performance. Based on our forecasts, it is anticipated that Tandem will maintain a workforce of about 2400 employees by February 2025.Tandem Diabetes' latest congressional trading
Congressional trading in companies like Tandem Diabetes Care, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Tandem Diabetes by those in governmental positions are based on the same information available to the general public.
2024-09-11 | Representative Josh Gottheimer | Acquired Under $15K | Verify |
Tandem Diabetes Management Team Effectiveness
The company has return on total asset (ROA) of (0.0969) % which means that it has lost $0.0969 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4596) %, meaning that it created substantial loss on money invested by shareholders. Tandem Diabetes' management efficiency ratios could be used to measure how well Tandem Diabetes manages its routine affairs as well as how well it operates its assets and liabilities. As of the 17th of January 2025, Return On Tangible Assets is likely to drop to -0.22. In addition to that, Return On Capital Employed is likely to grow to -0.34. At this time, Tandem Diabetes' Intangible Assets are very stable compared to the past year. As of the 17th of January 2025, Net Tangible Assets is likely to grow to about 531.2 M, while Intangibles To Total Assets are likely to drop 0.As of the 17th of January 2025, Common Stock Shares Outstanding is likely to grow to about 78.5 M, while Net Loss is likely to drop (114.2 M).
Tandem Diabetes Workforce Comparison
Tandem Diabetes Care is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 353,436. Tandem Diabetes maintains roughly 2,400 in number of employees contributing less than 1% to equities under Health Care industry.
The company has Profit Margin (PM) of (0.15) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.11) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.11. Tandem Diabetes Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tandem Diabetes insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tandem Diabetes' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Tandem Diabetes insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-12-01 | 0.6053 | 23 | 38 | 51,639 | 108,121 |
2024-09-01 | 0.5143 | 18 | 35 | 62,962 | 33,996 |
2024-06-01 | 1.0294 | 70 | 68 | 477,258 | 166,510 |
2024-03-01 | 0.5135 | 19 | 37 | 10,832 | 14,681 |
2023-12-01 | 0.6939 | 34 | 49 | 114,872 | 15,954 |
2023-09-01 | 0.5306 | 26 | 49 | 13,793 | 16,907 |
2023-06-01 | 1.1695 | 69 | 59 | 437,790 | 65,294 |
2023-03-01 | 2.1111 | 38 | 18 | 41,242 | 13,820 |
2022-12-01 | 2.3125 | 37 | 16 | 63,718 | 12,592 |
2022-09-01 | 1.5714 | 22 | 14 | 8,505 | 2,030 |
2022-06-01 | 3.6667 | 88 | 24 | 280,092 | 27,913 |
2022-03-01 | 1.4211 | 27 | 19 | 35,888 | 11,029 |
2021-12-01 | 1.641 | 64 | 39 | 284,976 | 1,152,208 |
2021-09-01 | 0.963 | 52 | 54 | 248,884 | 354,093 |
2021-06-01 | 0.9818 | 54 | 55 | 178,226 | 239,874 |
2021-03-01 | 0.2727 | 3 | 11 | 13,354 | 220,292 |
2020-12-01 | 0.2273 | 10 | 44 | 74,872 | 385,804 |
2020-09-01 | 0.4674 | 43 | 92 | 867,069 | 1,440,806 |
2020-06-01 | 1.3333 | 28 | 21 | 176,738 | 119,308 |
2020-03-01 | 0.5854 | 24 | 41 | 181,555 | 365,656 |
2019-12-01 | 0.3846 | 5 | 13 | 50,462 | 255,924 |
2019-09-01 | 0.4483 | 13 | 29 | 80,955 | 534,025 |
2019-06-01 | 1.0625 | 17 | 16 | 57,450 | 104,688 |
2019-03-01 | 0.5556 | 20 | 36 | 1,058,982 | 574,521 |
2018-12-01 | 1.0625 | 17 | 16 | 228,749 | 482,699 |
2018-06-01 | 2.6667 | 8 | 3 | 1,035,700 | 418,144 |
2018-03-01 | 1.5 | 12 | 8 | 1,958,121 | 114,236 |
2016-09-01 | 0.5 | 1 | 2 | 15,000 | 30,000 |
2016-06-01 | 1.5 | 6 | 4 | 15,415 | 8,000 |
2016-03-01 | 1.8333 | 11 | 6 | 753,250 | 16,000 |
2015-12-01 | 2.5 | 10 | 4 | 142,000 | 12,000 |
2015-09-01 | 0.2857 | 2 | 7 | 19,500 | 94,000 |
2015-06-01 | 3.0 | 12 | 4 | 449,838 | 8,000 |
2015-03-01 | 0.5 | 3 | 6 | 6,000 | 12,000 |
2014-12-01 | 2.5714 | 18 | 7 | 158,118 | 14,000 |
2014-09-01 | 0.5 | 3 | 6 | 6,000 | 12,000 |
2014-06-01 | 4.0 | 8 | 2 | 17,945 | 4,000 |
2013-12-01 | 0.6381 | 67 | 105 | 44,225,721 | 21,266,459 |
2009-03-01 | 0.2 | 1 | 5 | 3,169 | 4,044,302 |
2007-12-01 | 0.6154 | 8 | 13 | 13,860,388 | 20,860,582 |
Tandem Diabetes Notable Stakeholders
A Tandem Diabetes stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Tandem Diabetes often face trade-offs trying to please all of them. Tandem Diabetes' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Tandem Diabetes' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Brian Hansen | Chief Commercial Officer, Executive Vice President | Profile | |
Leigh Vosseller | Senior Vice President - Finance | Profile | |
JeanClaude Kyrillos | Executive COO | Profile | |
John Sheridan | COO and Executive VP | Profile | |
Shannon JD | Chief VP | Profile | |
Tom Fox | Chief Officer | Profile | |
Susan Morrison | Chief Admin. Officer | Profile | |
Mark Novara | Executive Officer | Profile | |
Ross Sylvia | VP Marketing | Profile | |
David Esq | Transitional Advisor | Profile | |
Jordan MD | Chief Officer | Profile | |
Libba Sapitsky | Senior Care | Profile | |
Rick Carpenter | Chief Officer | Profile | |
Elizabeth Gasser | Executive Officer | Profile | |
Shannon Hansen | Privacy Legal | Profile |
About Tandem Diabetes Management Performance
The success or failure of an entity such as Tandem Diabetes Care often depends on how effective the management is. Tandem Diabetes management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Tandem management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Tandem management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.21) | (0.22) | |
Return On Capital Employed | (0.35) | (0.34) | |
Return On Assets | (0.21) | (0.22) | |
Return On Equity | (0.82) | (0.78) |
Tandem Diabetes Workforce Analysis
Traditionally, organizations such as Tandem Diabetes use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Tandem Diabetes within its industry.Tandem Diabetes Manpower Efficiency
Return on Tandem Diabetes Manpower
Revenue Per Employee | 311.5K | |
Revenue Per Executive | 49.8M | |
Net Loss Per Employee | 92.8K | |
Net Loss Per Executive | 14.8M | |
Working Capital Per Employee | 230.3K | |
Working Capital Per Executive | 36.8M |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tandem Diabetes Care. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tandem Diabetes listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.37) | Earnings Share (1.94) | Revenue Per Share | Quarterly Revenue Growth 0.314 | Return On Assets |
The market value of Tandem Diabetes Care is measured differently than its book value, which is the value of Tandem that is recorded on the company's balance sheet. Investors also form their own opinion of Tandem Diabetes' value that differs from its market value or its book value, called intrinsic value, which is Tandem Diabetes' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tandem Diabetes' market value can be influenced by many factors that don't directly affect Tandem Diabetes' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tandem Diabetes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tandem Diabetes' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.